Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Plus Paclitaxel/Carboplatin in Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Or Fallopian Tube Cancer
NCT00096200Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2004
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sorafenib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Complete and Partial Response Rate at 6 weeks. Started Aug 2004; status: completed.
02
Drugs
sorafenib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00096200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096200.